Ujin Pharma

Here is a breakdown of their fundamentals, financials, and current IPO status to help you review or draft your listing:

📋 IPO Overview

• Issue Type: Book Built Issue IPO (Fresh Issue + Offer for Sale)

•         Total Issue Size: Up to 1.92 crore equity shares

  • Fresh Issue: ~1.19 crore shares

  • Offer for Sale (OFS): ~0.73 crore shares (offloaded by promoters Jinesh Rasiklal Sheth and Umang Ketan Mehta)

• Face Value: ₹10 per share

• Price Band & Dates: To be announced (since they have only recently filed the DRHP)

• Listing At: BSE and NSE

• Lead Managers: SMC Capitals Ltd. & Marwadi Chandarana Intermediaries Brokers Pvt. Ltd.

• Registrar: KFin Technologies Limited

📊 Financial Performance (Profit & Loss)

Ujin Pharma has shown steady revenue growth over the past few years, though its net profits dipped slightly in the latest full fiscal year due to changing operational expenses.

Key Ratios (FY25)

• Return on Net Worth (RoNW): 11.87%

• Return on Equity (ROE): 12.15%

• Debt to Equity Ratio: 1.57

🏢 Company Fundamentals & Business Model

• Core Business: Incorporated as a company in 2024 (evolving from over two decades of operational background as a partnership), Ujin Pharma is a major chemical distribution and supply chain company.

• Product Portfolio: They specialize in trading and distributing solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials, and nutraceuticals.

• Industry Footprint: They serve over 3,000 customers across pharmaceuticals, agrochemicals, paints, packaging, and petrochemicals. Their operational backup includes a massive sourcing network of over 1,200 suppliers and major warehousing setups in Bhiwandi (Maharashtra) and Kandla (Gujarat).

• Value Addition: Through their subsidiary, Shiv Shakti Oxalate (SSOPL), they run a manufacturing and chemical processing plant in Pune focusing on solvent recycling and recovery.

🎯 Objects of the Fresh Issue

Out of the fresh capital raised, the company intends to allocate:

1. ₹61.72 Crore: Investment in Altra Agro-Chem Private Limited to turn it into a subsidiary.

2. ₹21.64 Crore: Investment in Altra Pharma-Chem Private Limited to turn it into a subsidiary.

3. ₹25.00 Crore: Repayment or prepayment of certain institutional borrowings to lower debt.

   ipoind.com

4. Balance: General corporate purposes.

📈 Grey Market Premium (GMP)

⚠️ Current Status: N/A (Not Available) Since the price band and official public offer dates have not been declared by the company or lead managers yet, active grey market trading hasn’t commenced. Real-time GMP updates will only surface once SEBI clears the DRHP and the firm sets its official bidding window.ipoind.com